# rheumatoid arthritis - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: synovial tissue
- Comparison or endpoint: rheumatoid arthritis versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d868ce3efb219458b8d5ddb7b123eef3f2b718852ba0ede74f2a02e9181db293
- Response HTTP status: 200
- Prompt tokens: 31944
- Completion tokens: 11117
- Reasoning tokens: 0
- Total tokens: 43061
- API requests reported: 2
- Elapsed seconds: 80.323
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 984.622
- Question handoff seconds: 999.892
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: DeepSeek

---
# Multidimensional Interpretation of Rheumatoid Arthritis Synovial Transcriptomic Data

## 1. Overall Biological Interpretation

The current dataset contains **100 downregulated genes** (log2FC range approximately −2.28 to −5.10; all FDR < 4.4×10⁻³⁵) in rheumatoid arthritis (RA) synovial tissue compared with normal controls. Notably, there are **no upregulated genes** in this analysis. This unidirectional pattern is a critical interpretive constraint: the results describe a set of genes whose expression is suppressed in RA synovium, rather than a balanced picture of both activation and repression.

The dominant biological themes are:

- **Loss of epithelial/mucosal differentiation markers**: MUC5B, MUC6, MUC12, CDHR5, GRIFIN, and CEMP1 are all strongly downregulated. In synovial tissue, these are unusual because mucins are typically associated with mucosal surfaces. Their suppression may reflect either a genuine synovial phenotype change or, more likely, a **cell-composition effect**—if normal synovial samples contain contaminating epithelial or mucosal elements that are absent in RA samples.
- **Suppression of ciliary/centrosomal components**: CROCC, CROCC2, CROCCP2, and CCDC9 are all downregulated. These genes encode components of the ciliary rootlet and centrosome, suggesting altered cytoskeletal organization.
- **Downregulation of polarity and cell-adhesion regulators**: SCRIB, ARVCF, APC2, and GJC2 are all reduced. These genes participate in cell polarity, adherens junction regulation, and gap junction communication—processes relevant to synovial lining integrity.
- **Widespread reduction in non-coding RNA species**: multiple microRNAs (MIR3183, MIR3615, MIR3154, MIR937, MIR647, MIR4763, MIR4492, MIR4730, MIR6821, MIR4665, MIR1301), snoRNAs (SNORD167, SCARNA17), and long non-coding RNAs (PCGF3-AS1, CXXC5-AS1, TNK2-AS1, TBX2-AS1, LINC00685, LINC01786) are all downregulated. This broad non-coding RNA suppression is unusual and may reflect global transcriptional repression or technical artifacts.

**Critical data-quality warning**: The fact that *all 100 genes are downregulated* with extreme FDR values (many below 10⁻³⁵) is statistically suspicious. Such uniformly extreme P values across an entire gene set, combined with the presence of numerous uncharacterized LOC genes and non-coding RNAs, raises the possibility of a **batch effect, normalization artifact, or cell-composition difference** rather than a coherent disease biology. This does not invalidate the individual gene statistics, but it strongly cautions against interpreting the "programs" below as disease-causal mechanisms without independent validation.

---

## 2. Core Biological Programs

Given the uniform directionality and the nature of the gene set, I identify five programs. Each is supported by multiple genes, but all carry the caveat that they may reflect composition differences rather than RA-specific biology.

### Program 1: Suppressed Mucosal/Epithelial Differentiation Program
- **Direction**: Downregulated
- **Major supporting genes**: MUC5B (log2FC −4.43), MUC6 (−3.85), MUC12 (−4.27), CDHR5 (−4.22), GRIFIN (−3.62), CEMP1 (−2.49)
- **Standardized pathway**: GO:0030855 (epithelial cell differentiation); KEGG: Mucin type O-glycan biosynthesis
- **Explanation**: The coordinated suppression of multiple mucin genes and cadherin-related family member 5 indicates loss of a secretory epithelial differentiation program. STRING records show MUC12, MUC5B, and MUC6 cluster around MUC1/MUC2/MUC5AC/MUC7 hubs, supporting pathway co-membership. CDHR5 is a cadherin involved in intestinal epithelial differentiation; its loss alongside mucins suggests a shared regulatory program.
- **Evidence strength**: Moderate for the co-expression pattern (multiple genes, STRING network co-membership); **weak** for disease specificity—these are not canonical synovial genes, and their presence in normal synovium is itself questionable.
- **Major limitation**: The most parsimonious explanation is **contamination of normal controls with epithelial/mucosal tissue** or differential biopsy sampling depth.

### Program 2: Suppressed Cell Polarity and Adherens Junction Signaling
- **Direction**: Downregulated
- **Major supporting genes**: SCRIB (−3.24), ARVCF (−3.46), APC2 (−3.02), GJC2 (−3.50), PPP1R12C (−2.70)
- **Standardized pathway**: KEGG: Hippo signaling pathway (retrieved in batch); Reactome: CDC42/RHOQ GTPase cycles (SCRIB records)
- **Explanation**: SCRIB is a core cell-polarity scaffold (STRING: interacts with LLGL1, VANGL2, GIT1). ARVCF is a catenin that binds CTNNB1 (β-catenin) and COMT (STRING confidence 0.897 and 0.804). APC2 is an adenomatous polyposis coli paralog that regulates β-catenin degradation. The coordinated downregulation of these polarity/catenin regulators, alongside the Hippo pathway annotation, suggests a program of altered cell-cell contact signaling and polarity that could affect synovial lining barrier function.
- **Evidence strength**: Moderate—multiple genes, coherent pathway annotations, and documented protein interactions (STRING). However, the STRING interactions are **predicted/curated co-membership and physical interaction records**, not direct experimental evidence from synovium.
- **Major limitation**: Whether suppressed polarity genes contribute to RA or reflect loss of a particular synovial cell type (e.g., lining macrophages or fibroblast-like synoviocytes) cannot be resolved from bulk transcriptomics.

### Program 3: Suppressed Ciliary and Centrosomal Architecture
- **Direction**: Downregulated
- **Major supporting genes**: CROCC (−3.88), CROCC2 (−4.99), CROCCP2 (−2.89), CCDC9 (−3.02), CCDC154 (−3.30), TELO2 (−3.07)
- **Standardized pathway**: GO:0005813 (centrosome); GO:0005929 (cilium); Reactome: not specifically retrieved
- **Explanation**: CROCC (ciliary rootlet coiled-coil) and its paralogs form a clear gene family cluster (STRING: CROCC/CROCC2/LRRC45 module). CCDC9 and CCDC154 are coiled-coil domain proteins associated with centrosomal/ciliary structures. TELO2 is involved in DNA damage signaling and mTOR complex assembly. The coordinated suppression suggests loss of ciliary/centrosomal components in RA synovium.
- **Evidence strength**: Moderate for gene-family co-regulation; **weak** for disease relevance—ciliary genes are not established RA drivers, and their suppression may reflect loss of a specific cell population.
- **Major limitation**: No functional connection between primary cilia and RA synovitis is established in the retrieved literature.

### Program 4: Suppressed Transcriptional/Epigenetic Regulators
- **Direction**: Downregulated
- **Major supporting genes**: ZNF316 (−3.24), ZNF219 (−2.71), ZNF444 (−2.46), ZNF580 (−2.76), CBX7 (−2.41), SIX5 (−2.86), HDGFL2 (−2.37), PAGR1 (−2.34), SCAF1 (−3.30), TNRC18 (−3.04)
- **Standardized pathway**: GO:0003677 (DNA binding); GO:0005634 (nucleus); no specific KEGG pathway retrieved
- **Explanation**: Multiple zinc-finger transcription factors, the chromobox protein CBX7 (a Polycomb repressive complex 1 component), the homeobox factor SIX5, and the transcriptional co-regulator PAGR1 are all suppressed. SCAF1 is involved in RNA polymerase II C-terminal domain coupling. This pattern suggests broad transcriptional repression, but the genes are functionally diverse and do not form a single coherent regulatory cascade.
- **Evidence strength**: Weak-to-moderate—many genes share the GO term "nucleus/protein binding," but this is a broad annotation with low specificity. The genes are not known to interact directly.
- **Major limitation**: The apparent "program" may simply reflect a global reduction in nuclear gene expression, which is consistent with the data-quality concern of a normalization or composition artifact.

### Program 5: Suppressed Non-Coding RNA and RNA-Processing Machinery
- **Direction**: Downregulated
- **Major supporting genes**: MIR3183 (−4.61), MIR3154 (−5.10), MIR937 (−3.70), MIR647 (−3.83), MIR3615 (−4.13), MIR4492 (−4.20), SNORD167 (−3.28), SCARNA17 (−3.83), RNA5-8SN2 (−5.10), RNA5-8SN3 (−4.57), RNA5-8SN4 (−5.00), ELOA3BP (−3.53), ELOA3P (−3.43), CNOT12 (−2.94), EXD3 (−3.20)
- **Standardized pathway**: KEGG: Ribosome biogenesis in eukaryotes; Ribosome (retrieved in batch)
- **Explanation**: The suppression of multiple microRNAs, small nucleolar RNAs, 5.8S rRNA pseudogenes, and RNA-binding proteins (CNOT12 is a CCR4-NOT complex subunit; EXD3 is an exonuclease) suggests a broad reduction in RNA processing and ribosome biogenesis. The KEGG "Ribosome biogenesis in eukaryotes" and "Ribosome" annotations were retrieved for this cohort.
- **Evidence strength**: Weak—the presence of many uncharacterized LOC genes, pseudogenes (ELOA3P, ELOA3BP, CROCCP2), and rRNA pseudogenes (RNA5-8SN2/3/4) in the most extreme downregulated set is a **red flag for technical artifacts** (e.g., mappability issues, multi-mapping reads, or differential GC-content normalization).
- **Major limitation**: Non-coding RNA and pseudogene measurements are highly sensitive to library preparation and alignment methodology; these results require technical validation by qPCR or orthogonal methods before biological interpretation.

---

## 3. Key Genes and Interaction Modules

I identify the following key genes/modules, selected for their statistical strength, biological coherence, and network evidence. None should be interpreted as causal without validation.

### 3.1 SCRIB — Cell Polarity Scaffold
- **Dataset direction**: Downregulated (log2FC −3.24, FDR 1.32×10⁻⁴²)
- **Role in programs**: Core member of the cell polarity/adherens junction program.
- **Interaction evidence**: STRING records show high-confidence interactions with ARHGEF7 (0.997), VANGL2 (0.996), GIT1 (0.983), UBE3A (0.980), and LLGL1 (0.964). Reactome places SCRIB in CDC42/RHOQ/RND GTPase cycles. These are **direct physical interaction records** from STRING, but they are not derived from synovial tissue and represent general protein-interaction evidence.

### 3.2 ARVCF — Catenin/β-Catenin Module
- **Dataset direction**: Downregulated (log2FC −3.46, FDR 1.01×10⁻³⁸)
- **Role in programs**: Cell polarity and adherens junction signaling; links to CTNNB1 (β-catenin).
- **Interaction evidence**: STRING shows interaction with COMT (0.897), TXNRD2 (0.860), ERBIN (0.831), CTNNB1 (0.804), and FMR1 (0.797). The ARVCF-CTNNB1 edge is a **direct physical interaction** record; the ARVCF-COMT edge is also STRING-curated physical interaction. The connection to β-catenin signaling is biologically plausible given ARVCF's role as a catenin, but this is **pathway co-membership plus interaction records**, not direct evidence of Hippo/β-catenin dysregulation in this cohort.

### 3.3 APC2 — β-Catenin Degradation Regulator
- **Dataset direction**: Downregulated (log2FC −3.02, FDR 4.63×10⁻³⁹)
- **Role in programs**: Hippo/Wnt signaling; APC2 is a negative regulator of Wnt/β-catenin signaling.
- **Interaction evidence**: STRING module places APC2 with CTNNB1. The relationship is **pathway co-membership** (Wnt/β-catenin degradation complex) supported by STRING interaction records; no direct physical interaction in synovium is demonstrated here.

### 3.4 MUC Gene Family Module (MUC5B, MUC6, MUC12)
- **Dataset directions**: MUC5B (−4.43), MUC6 (−3.85), MUC12 (−4.27)
- **Role in programs**: Mucosal/epithelial differentiation program.
- **Interaction evidence**: STRING places MUC12, MUC5B, and MUC6 in a network with MUC1, MUC2, MUC5AC, and MUC7. This is **pathway co-membership** (mucin family) and possibly shared regulatory elements; it is not evidence of direct physical interaction between mucin proteins.

### 3.5 CROCC/CROCC2 Module
- **Dataset directions**: CROCC (−3.88), CROCC2 (−4.99), CROCCP2 (−2.89)
- **Role in programs**: Ciliary/centrosomal architecture.
- **Interaction evidence**: STRING places CROCC and CROCC2 with LRRC45. These are **gene-family paralogs** sharing sequence and structural features; the STRING edges likely reflect paralogy and co-expression rather than direct physical interaction.

### 3.6 GJC2 — Gap Junction Protein
- **Dataset direction**: Downregulated (log2FC −3.50, FDR 5.11×10⁻⁴⁰)
- **Role in programs**: Cell-cell communication; gap junction formation.
- **Interaction evidence**: STRING shows interactions with FAM126A, PNPLA6, AP5Z1, SPG21, and GJB2. These are **physical interaction records** from STRING, but they are not specific to synovium.

### 3.7 CBX7 — Polycomb Repression
- **Dataset direction**: Downregulated (log2FC −2.41, FDR 1.43×10⁻³⁵)
- **Role in programs**: Epigenetic/transcriptional regulation.
- **Interaction evidence**: CBX7 is a component of Polycomb repressive complex 1 (PRC1). Its interaction with other PRC1 components is **pathway co-membership**; no specific PRC1 interaction records were retrieved in this batch.

### 3.8 DMPK — Myotonic Dystrophy Kinase
- **Dataset direction**: Downregulated (log2FC −2.97, FDR 1.87×10⁻³⁶)
- **Role in programs**: Not clearly assigned to a single program; DMPK is a serine/threonine kinase involved in muscle differentiation and RNA metabolism (via the DM1-AS locus, also downregulated).
- **Interaction evidence**: DM1-AS (log2FC −3.65) is an antisense transcript at the DMPK locus. The relationship between DM1-AS and DMPK is **regulatory interaction** (antisense-mediated regulation), not direct physical interaction.

### 3.9 SH2B1 — Signaling Adapter
- **Dataset direction**: Downregulated (log2FC −2.28, FDR 8.10×10⁻³⁶)
- **Role in programs**: Not clearly assigned; SH2B1 is an adapter protein involved in JAK/STAT and insulin signaling.
- **Interaction evidence**: No specific interaction records retrieved in this batch.

### 3.10 PIDD1/NOL3 Module — Apoptosis Regulation
- **Dataset directions**: PIDD1 (−2.89), NOL3 (−2.45)
- **Role in programs**: Not clearly assigned; both are involved in apoptosis regulation.
- **Interaction evidence**: STRING places NOL3 and PIDD1 with CASP2. This is a **pathway co-membership** in the PIDDosome/caspase-2 activation complex; NOL3 and PIDD1 may regulate CASP2-mediated apoptosis, but this is an indirect/putative relationship in the context of RA.

---

## 4. Validation Priorities

### Validation Priority 1: Cell-Composition and Contamination Check
- **Classification**: Confounding or composition check
- **Why prioritize**: The uniform downregulation of 100 genes, including mucins, ciliary genes, and epithelial markers, is most parsimoniously explained by differences in tissue composition between RA and normal synovial samples. This could invalidate all downstream biological interpretation.
- **Current dataset evidence**: 100/100 genes downregulated; presence of MUC5B/MUC6/MUC12 (epithelial markers) and numerous uncharacterized LOC genes in the top hits.
- **External evidence**: Mucins are not canonical synovial lining markers; their presence suggests epithelial contamination in controls. No independent-cohort statistics are available.
- **Next step**: Perform deconvolution (e.g., CIBERSORTx or single-cell reference-based deconvolution) to estimate cell-type fractions; validate by immunohistochemistry for mucins and epithelial markers in matched RA and normal synovium; repeat analysis after excluding epithelial/mucosal marker genes.
- **Conclusion status**: **Exploratory hypothesis** — the composition confound is plausible but not yet demonstrated.

### Validation Priority 2: Technical Artifact Check for Non-Coding RNA and Pseudogene Signals
- **Classification**: Confounding or composition check
- **Why prioritize**: MicroRNAs, snoRNAs, rRNA pseudogenes (RNA5-8SN2/3/4), and uncharacterized LOC genes dominate the most extreme downregulated set. These are prone to alignment, mappability, and normalization artifacts.
- **Current dataset evidence**: Multiple miRNA/snoRNA/rRNA-pseudogene genes with log2FC < −3.5 and FDR < 10⁻³⁵.
- **External evidence**: No independent-cohort statistics available. Literature (e.g., PMID 36983764) discusses miRNA measurement variability across platforms.
- **Next step**: Validate a panel of the top non-coding RNAs by qRT-PCR with specific probes; check multi-mapping read fractions; re-quantify using an aligner that handles multi-mappers explicitly; compare results using an alternative normalization method (e.g., TMM vs. RLE).
- **Conclusion status**: **Exploratory hypothesis** — technical artifact is possible but not confirmed.

### Validation Priority 3: Cell Polarity/Hippo Signaling in Synovial Fibroblast-Like Synoviocytes
- **Classification**: Mechanistic hypothesis
- **Why prioritize**: SCRIB, ARVCF, and APC2 form a coherent polarity/β-catenin module with documented interactions. If confirmed, this could reveal a novel pathway in RA synovial lining dysfunction.
- **Current dataset evidence**: SCRIB (−3.24), ARVCF (−3.46), APC2 (−3.02) all significantly downregulated; STRING interaction records support a β-catenin-centered module.
- **External evidence**: The Hippo signaling pathway was retrieved in the KEGG batch. However, no RA-specific literature was retrieved linking these genes to synovitis. External statistical validation was not performed.
- **Next step**: Isolate fibroblast-like synoviocytes (FLS) from RA and normal synovium; measure SCRIB, ARVCF, APC2, and β-catenin target genes (e.g., CTGF, CYR61) by qPCR; perform siRNA knockdown of SCRIB in normal FLS and assess proliferation, migration, and β-catenin reporter activity.
- **Conclusion status**: **Supported hypothesis** (for the co-expression pattern) — mechanistic causality is **not established**.

### Validation Priority 4: Mucin Expression as a Synovial Lining Integrity Marker
- **Classification**: Biomarker
- **Why prioritize**: If mucin suppression reflects genuine synovial changes (rather than contamination), it could serve as a novel biomarker for synovial lining disruption.
- **Current dataset evidence**: MUC5B (−4.43), MUC6 (−3.85), MUC12 (−4.27) strongly downregulated.
- **External evidence**: Mucins are not established RA biomarkers. The retrieved literature does not address mucins in RA synovium. External statistical validation was not performed.
- **Next step**: Measure MUC5B/MUC6/MUC12 protein and mRNA in synovial fluid and synovial tissue by ELISA and qPCR; correlate with disease activity scores (DAS28); test in an independent RA cohort.
- **Conclusion status**: **Exploratory hypothesis** — biomarker potential is unproven.

### Validation Priority 5: Ciliary Gene Suppression in RA Synovial Cell Types
- **Classification**: Mechanistic hypothesis
- **Why prioritize**: CROCC/CROCC2 suppression is consistent across multiple paralogs and may indicate loss of a specific synovial cell type (e.g., primary cilia-bearing lining cells).
- **Current dataset evidence**: CROCC (−3.88), CROCC2 (−4.99), CROCCP2 (−2.89) all downregulated.
- **External evidence**: No retrieved literature connects primary cilia to RA. The STRING module (CROCC/CROCC2/LRRC45) supports gene-family co-regulation but not disease causality.
- **Next step**: Perform immunofluorescence for acetylated tubulin (primary cilia marker) and CROCC in RA and normal synovium; use single-cell RNA-seq to determine which cell types express these genes and whether they are depleted in RA.
- **Conclusion status**: **Exploratory hypothesis** — no causal evidence.

---

## 5. Evidence Grounding

| Claim | Direct input evidence | Pathway/ontology | Protein interaction/regulatory | Disease-association | Expression/tissue | Genetic/clinical | Drug/therapeutic | Literature |
|---|---|---|---|---|---|---|---|---|
| 100 genes downregulated | Yes (all FDR < 4.4×10⁻³⁵) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Mucin/epithelial suppression | Yes (MUC5B, MUC6, MUC12, CDHR5) | GO: epithelial differentiation | STRING: mucin family co-membership | Weak (not RA-specific) | GTEx/HPA records available for some genes | No GWAS signal retrieved | No drug evidence | No RA-specific mucin literature retrieved |
| Cell polarity/Hippo suppression | Yes (SCRIB, ARVCF, APC2) | KEGG: Hippo; Reactome: GTPase cycles | STRING: SCRIB-LLGL1/VANGL2; ARVCF-CTNNB1 | Weak | HPA/GTEx records available | No RA GWAS signal | No drug evidence | No RA-specific literature retrieved |
| Ciliary/centrosomal suppression | Yes (CROCC, CROCC2, CCDC9) | GO: centrosome/cilium | STRING: CROCC-CROCC2-LRRC45 (paralogy) | Weak | GTEx records available | No RA GWAS signal | No drug evidence | No RA-specific literature retrieved |
| Non-coding RNA suppression | Yes (multiple MIR, SNORD, RNA5-8SN) | KEGG: Ribosome biogenesis | No interaction evidence | Weak | GTEx records partial | No RA GWAS signal | No drug evidence | Limited (miRNA measurement variability, PMID 36983764) |

**Independence assessment**: The STRING, Reactome, and QuickGO records for SCRIB/ARVCF/APC2 derive from overlapping databases that share underlying publications and prediction models; they are **not independent** sources. The KEGG "Hippo signaling" annotation and the STRING CTNNB1 module both point to the same β-catenin pathway but may share underlying literature. The mucin STRING module and the epithelial differentiation GO term are also likely derived from overlapping gene-annotation sources. Therefore, the pathway-level support for the polarity and mucin programs is **partially redundant**, not multiply independent.

**External statistical validation**: Not performed. No independent-cohort statistics (HR, log2FC, P, FDR) from a separate RA cohort were supplied. Pathway recurrence, STRING edges, and literature records do not constitute replication.

---

## 6. Limitations and Alternative Explanations

### Limitation 1: Cell-Composition Differences Between RA and Normal Synovium
- **Impact**: High. If normal controls contain more epithelial/mucosal cells, fibroblasts, or lining cells than RA samples, all "downregulated" genes could simply reflect cell-type depletion rather than transcriptional repression.
- **How to investigate**: Single-cell RNA-seq of matched RA and normal synovium; computational deconvolution (CIBERSORTx, BisqueRNA) using a synovial reference panel; immunohistochemistry for cell-type markers.

### Limitation 2: Batch Effects and Platform Artifacts
- **Impact**: High. The extreme P values (many < 10⁻³⁵), the uniform directionality, and the presence of rRNA pseudogenes and uncharacterized LOC genes suggest possible normalization artifacts (e.g., GC-content bias, multi-mapping read misassignment, or library-size normalization failure).
- **How to investigate**: Examine PCA/UMAP for batch separation; compare results across normalization methods; verify top genes by qPCR; check alignment statistics (multi-mapping rate, rRNA contamination).

### Limitation 3: Disease Severity and Treatment Exposure
- **Impact**: Moderate. RA patients are typically on immunosuppressive therapy (methotrexate, biologics, corticosteroids) at the time of synovial biopsy, whereas normal controls are untreated. Treatment-induced transcriptional suppression could explain the uniform downregulation.
- **How to investigate**: Stratify RA patients by treatment status; analyze drug-naïve early RA samples; compare with published treatment-response transcriptomic datasets.

### Limitation 4: Association Versus Causation
- **Impact**: Moderate. Even if the gene expression changes are real, this cross-sectional design cannot distinguish cause from consequence. Downregulated polarity genes could be a result of synovial inflammation rather than a driver.
- **How to investigate**: Longitudinal sampling; Mendelian randomization using eQTL data; functional perturbation studies in FLS.

### Limitation 5: Broad, Non-Specific Pathway Enrichment
- **Impact**: Moderate. Many genes share only broad GO terms (e.g., "protein binding," "nucleus"), which can create the appearance of coherent programs where none exist. The "ribosome biogenesis" KEGG annotation may reflect rRNA pseudogene alignment artifacts rather than true biological repression.
- **How to investigate**: Use gene-set enrichment with background correction and competitive tests; restrict to curated, tissue-specific gene sets; require at least 3–5 genes per program with documented functional relationships.

---

## Summary

This dataset provides **statistically robust evidence** that 100 genes are downregulated in RA synovium relative to normal controls, but the biological interpretation is constrained by three major caveats: (1) the uniform downregulation of all genes suggests a possible composition or technical artifact; (2) the presence of epithelial/mucosal markers in the downregulated set raises contamination concerns; and (3) no independent-cohort validation was performed. The most defensible biological hypotheses are the suppression of cell polarity/Hippo signaling (SCRIB, ARVCF, APC2) and the loss of ciliary components (CROCC/CROCC2), but both require validation in isolated cell populations and independent cohorts before any causal or translational claims can be made. External statistical validation was not performed, and the pathway and interaction evidence retrieved from databases should be treated as contextual support rather than replication.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 84/100 selected items (records returned); cbioportal 82/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 19/100 selected items (records returned); clinvar 79/100 selected items (records returned); ensembl 40/100 selected items (partially returned; some queries failed); europepmc 776 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 61/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 47/100 selected items (records returned); humanbase 88/100 selected items (partially returned; some queries failed); intact 47/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 17/100 selected items (records returned); opentargets 82/100 selected items (records returned); pubmed 483 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 50/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 51/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 8/100 selected items (records returned); string 49/100 selected items (records returned); trrust 7/100 selected items (records returned)
